Drug shortage
Dobutamine Hydrochloride Injection · Hospira, Inc., a Pfizer Company
FDA drug shortage · Current · updated Apr 11, 2025
Key facts
| Generic name | Dobutamine Hydrochloride Injection |
|---|---|
| Proprietary name | Dobutamine Hydrochloride In Dextrose 5% In Plastic Container |
| Company | Hospira, Inc., a Pfizer Company |
| Presentation | Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32) |
| Dosage form | Injection |
| Strength | 1,000 mg/250mL (400 mg/mL) |
| Status | Current |
| Reason for shortage | Demand increase for the drug |
| Therapeutic category | Cardiovascular Pediatric Renal |
| Package NDCs | 0409-3724-32 |
| First posted | Nov 6, 2017 |
| Last updated | Apr 11, 2025 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: